The FY2025 (Dec) proxy of BridgeBio Pharma names 21 peer companies for pay. Among BridgeBio Pharma and these peers, CEO pay was 6th highest of 9 and total shareholder return was 8th highest of 9.
6th highest of 9in BridgeBio Pharma and its pay peers, FY2025 (Dec) by CEO pay:
$6.9M$33.2M
8th highest of 9in BridgeBio Pharma and its pay peers, FY2025 (Dec) by total shareholder return:
$17$524
Pay peer group, FY2025 (Dec) proxy
| Exelixis | ||
| Incyte | ||
| PTC Therapeutics | ||
| Halozyme Therapeutics | ||
| Madrigal Pharmaceuticals | ||
| Ionis Pharmaceuticals | ||
| Ultragenyx Pharmaceutical | ||
| Neurocrine Biosciences | ||
| Acadia Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| BioMarin Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Biohaven Ltd. | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Cytokinetics, Incorporated | Not disclosed | Not disclosed |
| Iovance Biotherapeutics, Inc | Not disclosed | Not disclosed |
| Jazz Pharmaceuticals Public Limited Company | Not disclosed | Not disclosed |
| Roivant Sciences | Not disclosed | Not disclosed |
| Sarepta Therapeutics, Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
21 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.